Advertisement

Topics

Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors

07:01 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Study will evaluate the potential of this novel combination in multiple solid tumors, including advanced renal cell carcinoma and urothelial carcinoma – – Expect to begin patient enrollment mid-year 2017 – ...

Other Sources for this Article

Investors:
Exelixis, Inc.
Susan Hubbard, 650-837-8194
EVP, Public Affairs and Investor Relations
shubbard@exelixis.com
or
Media:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcomllc.com

NEXT ARTICLE

More From BioPortfolio on "Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...